p.113 抽出テキスト
726. O’Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012;98:116–125. https:// doi.org/10.1136/hrt.2010.217182 727. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2011;57:2346–2355. https://doi.org/10.1016/j.jacc.2011.02.033 728. Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J 2013;77:2366–2374. https:// doi.org/10.1253/circj.CJ-12-1561 729. Shah A, Duncan K, Winson G, Chaudhry FA, Sherrid MV. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocardiography 2009;26:922–933. https://doi. org/10.1111/j.1540-8175.2009.00905.x 730. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J 1989;61:178–181. https://doi.org/10.1136/hrt.61.2.178 731. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg 2012;27:443–448. https://doi.org/10.1111/j.1540-8191.2012.01475.x 732. Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, et al. Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg 2013;96:564–570. https://doi.org/10.1016/j. athoracsur.2013.04.073 733. Gao X-J, Kang L-M, Zhang J, Dou K-F, Yuan J-S, Yang Y-J. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm and sustained ventricular tachycardia: a case report and literature review. Chin Med J (Engl) 2011;124:1754–1757. 734. Takeda I, Sekine M, Matsushima H, Hosomi N, Nakamura T, Ohtsuki T, et al. Two cases of cerebral embolism caused by apical thrombi in midventricular obstructive cardiomyopathy. Intern Med 2011;50:1059–1060. https://doi.org/10.2169/ internalmedicine.50.5079 735. Sato Y, Matsumoto N, Matsuo S, Yoda S, Tani S, Kasamaki Y, et al. Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation of possible causes of aneurysm formation. Yonsei Med J 2007;48:879–882. https://doi. org/10.3349/ymj.2007.48.5.879 736. Papanastasiou CA, Zegkos T, Kokkinidis DG, Parcharidou D, Karamitsos TD, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 2021;339:108. https:// doi.org/10.1016/j.ijcard.2021.07.025 737. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 2017;69:761–773. https://doi.org/10.1016/j. jacc.2016.11.063 738. Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 2016;18:1106–1118. https://doi.org/10.1002/ejhf.541 739. Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail 2018;11:e004124. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004124 740. Bourmayan C, Razavi A, Fournier C, Dussaule JC, Baragan J, Gerbaux A, et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am Heart J 1985;109:1311–1316. https://doi.org/10.1016/0002- 8703(85)90357-6 741. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 1982;48: 204–212. https://doi.org/10.1136/hrt.48.3.204 742. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J 1986;56:544–553. https://doi.org/10.1136/hrt.56.6. 544 743. Udelson JE, Bonow RO, O’Gara PT, Maron BJ, Van Lingen A, Bacharach SL, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79: 1052–1060. https://doi.org/10.1161/01.CIR.79.5.1052 744. Pacileo G, De Cristofaro M, Russo MG, Sarubbi B, Pisacane C, Calabro R. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. Can J Cardiol 2000;16:146–152. 745. Cappelli F, Morini S, Pieragnoli P, Targetti M, Stefano P, Marchionni N, et al. Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria. J Am Coll Cardiol 2018;71:464–466. https://doi.org/10.1016/j. jacc.2017.11.040 746. Killu AM, Park J-Y, Sara JD, Hodge DO, Gersh BJ, Nishimura RA, et al. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. Europace 2018;20:82–88. https://doi.org/10.1093/europace/euw327 747. Gu M, Jin H, Hua W, Fan X-H, Niu H-X, Tian T, et al. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy. J Geriatr Cardiol 2017;14:238–244. https://doi.org/10.11909/j.issn.1671-5411.2017.04.002 748. Ahmed I, Loudon BL, Abozguia K, Cameron D, Shivu GN, Phan TT, et al. Biventricular pacemaker therapy improves exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. Eur J Heart Fail 2020;22:1263–1272. https://doi.org/10.1002/ejhf.1722 749. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92: 785–791. https://doi.org/10.1136/hrt.2005.068577 750. Barriales-Villa R, Centurion-Inda R, Fernandez-Fernandez X, Ortiz MF, Perez-Alvarez L, Rodriguez Garcia I, et al. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2010;63: 985–988. https://doi.org/10.1016/S0300-8932(10)70210-4 751. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988;318:1255–1257. https://doi.org/10.1056/NEJM198805123181907 752. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701–704. https://doi.org/10.1016/S0735-1097(86)80484-3 753. Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br Heart J 1980;43:245–251. https://doi.org/10.1136/hrt.43.3.245 754. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic obstructive cardiomyopathy due to asystole. Br Heart J 1972;34:974–976. https://doi.org/10.1136/hrt.34.9.974 755. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984;59:971–975. https://doi.org/10.1136/adc.59.10.971 756. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147–153. https://doi.org/10.1016/0735- 1097(88)90181-7 757. Ostman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, et al. Ageand gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008;29:1160–1167. https://doi.org/10.1093/eurheartj/ehn122 758. Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013;382:1889–1897. https://doi. org/10.1016/S0140-6736(13)61685-2 759. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 2021;42:1988–1996. https://doi.org/10.1093/eurheartj/ehab148 760. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003;108:2342–2348. https://doi.org/10.1161/01.CIR. 0000097110.55312.BF 761. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41: 987–993. https://doi.org/10.1016/S0735-1097(02)03004-8 762. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–778. https://doi. org/10.1016/S0002-9149(98)00455-X 763. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005;45:1076–1080. https://doi.org/10. 1016/j.jacc.2004.12.067 764. D’Andrea A, Caso P, Severino S, Cuomo S, Capozzi G, Calabro P, et al. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1311–1318. https://doi.org/10.1093/eurheartj/ ehi688 765. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873–879. https://doi.org/10.1016/S0735-1097(03)00827-1 766. Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. Am J Cardiol 2003;91:1195–1198. https://doi.org/10.1016/S0002-9149(03)00266-2 767. Norrish G, Cleary A, Field E, Cervi E, Boleti O, Ziolkowska L, et al. Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy. J Am Coll Cardiol 2022;79:1986–1997. https://doi.org/10.1016/j.jacc.2022.03.347 768. Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599–2605. https://doi.org/ 10.1093/eurheartj/ehp327 769. Dimitrow PP, Chojnowska L, Rudzinski T, Piotrowski W, Ziolkowska L, Wojtarowicz A, et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a ESC Guidelines 3615 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026